• Diabetes

Nesina Generic Name & Formulations

General Description

Alogliptin 6.25mg, 12.5mg, 25mg; tabs.

Pharmacological Class

Dipeptidyl peptidase-4 (DPP-4) inhibitor.

How Supplied

Tabs 6.25mg—30, 90; 12.5mg, 25mg—30, 90, 500

Generic Availability


Nesina Indications


Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Limitations of Use

Not for treatment of type 1 diabetes.

Nesina Dosage and Administration


25mg once daily. Renal impairment: moderate (CrCl ≥30–<60mL/min): 12.5mg once daily; severe (CrCl ≥15–<30mL/min) or ESRD (CrCl <15mL/min or need hemodialysis): 6.25mg once daily.


Not established.

Nesina Contraindications

Not Applicable

Nesina Boxed Warnings

Not Applicable

Nesina Warnings/Precautions


Assess renal function prior to therapy and periodically thereafter. Monitor for signs/symptoms of pancreatitis, serious hypersensitivity reactions, or severe joint pain; discontinue if suspected or occurs. Consider risks/benefits in patients with known risk factors for heart failure; monitor for signs/symptoms; evaluate and consider discontinuing if develops. History of angioedema to other DPP-4 inhibitors. Hepatic impairment. Obtain LFTs before starting therapy; interrupt and evaluate if liver enzymes elevated or abnormal tests persist; do not restart if liver injury is confirmed and no other etiology can be found. Pregnancy (Cat.B). Nursing mothers.

Nesina Pharmacokinetics

See Literature

Nesina Interactions


May need lower dose of concomitant sulfonylurea or insulin to reduce risk of hypoglycemia.

Nesina Adverse Reactions

Adverse Reactions

Nasopharyngitis, headache, upper respiratory tract infection; pancreatitis, heart failure, hypersensitivity reactions (eg, anaphylaxis, angioedema, Stevens-Johnson syndrome), hepatic failure (may be fatal), severe and disabling arthralgia, bullous pemphigoid.

Nesina Clinical Trials

See Literature

Nesina Note

Not Applicable

Nesina Patient Counseling

See Literature